ABIOMED Company Profile (NASDAQ:ABMD)

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, May, 4th. The company reported $0.33 EPS for the quarter, hitting the Zacks' consensus estimate of $0.33. The firm earned $124.68 million during the quarter, compared to analysts' expectations of $122.82 million. ABIOMED had a return on equity of 12.67% and a net margin of 11.70%. The company's quarterly revenue was up 32.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.24 EPS. View ABIOMED's Earnings History.

ABIOMED is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for ABIOMED.

6 equities research analysts have issued twelve-month price targets for ABIOMED's shares. Their forecasts range from $145.00 to $170.00. On average, they anticipate ABIOMED's stock price to reach $152.00 in the next year. View Analyst Ratings for ABIOMED.

Here are some recent quotes from research analysts about ABIOMED stock:

• 1. According to Zacks Investment Research, "ABIOMED Inc. posted a stellar third quarter of fiscal 2017, beating the Zacks Consensus Estimate on both the counts. Over the past six months ABIOMED has outperformed the broader industry trends in terms of price performance. However, an unfavorable estimate revision trend for the current quarter indicates looming concern ahead of the stock. Intensifying competition in the niche markets is likely to mar the company’s prospects over the long haul. Although Abiomed’s significant international presence helps broaden its customer base, fluctuations in currency exchange rates may impact the company’s international sales. Nevertheless, the flagship Impella product line is a significant growth catalyst for the company." (1/30/2017)
• 2. Jefferies Group LLC analysts commented, "We hosted ABMD management for a series of meetings. As can be expected for a company that is growing revenue 40%+ and for a stock that has increased 33% this year (after 137% last year), the discussions focused on the sustainability of the company’s growth prospects. The outlook remains very encouraging and we offer some observations below. ABMD remains a top pick. ABMD remains at top pick. There are few growth stories that rival ABMD for large, under penetrated markets; established reimbursement; and no appreciable competition. Since the first PMA approval five quarters ago, the company has seen US Impella revenue growth average 49%. The company still only sells about 15k pumps a year in the US despite a market opportunity that is over 200k, a penetration rate of just 7%." (8/9/2016)

Some companies that are related to ABIOMED include Varian Medical Systems (VAR), PerkinElmer (PKI), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX), ABAXIS (ABAX), Natus Medical Incorporated (BABY), Quidel Corporation (QDEL), Mazor Robotics (MZOR), GenMark Diagnostics (GNMK), LeMaitre Vascular (LMAT), Accuray Incorporated (ARAY), ViewRay (VRAY), Corindus Vascular Robotics (CVRS), Viveve Medical (VIVE), Alliance HealthCare Services (AIQ), FULGENT GENETIC (FLGT) and Cytosorbents Corporation (CTSO).

ABIOMED's management team includes the folowing people:

• Michael R. Minogue, Chairman of the Board, President, Chief Executive Officer
• Michael J. Tomsicek, Chief Financial Officer, Vice President, Treasurer
• David M. Weber, Chief Operating Officer
• William J. Bolt, Senior Vice President - Global Product Operations
• Andrew J. Greenfield, Vice President, General Manager - Global Marketing
• Michael G. Howley, Vice President, General Manager - Global Sales and Marketing
• Dorothy E. Puhy, Lead Independent Director
• Jeannine M. Rivet, Director
• Christopher D. Van Gorder, Director
• Eric A. Rose M.D., Independent Director

ABIOMED's stock is owned by a number of of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (0.00%), BlackRock Inc. (0.00%), Vanguard Group Inc. (0.00%), Wellington Management Group LLP (0.00%), Palo Alto Investors LLC (4.41%) and Baillie Gifford & Co. (0.00%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Granahan Investment Management Inc. MA, Next Century Growth Investors LLC, Scout Investments Inc., First Trust Advisors LP, Russell Investments Group Ltd., Vanguard Group Inc. and Capital Fund Management S.A.. Company insiders that have sold ABIOMED stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley and Michael R Minogue. View Insider Buying and Selling for ABIOMED.

ABIOMED's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Baillie Gifford & Co., Brown Capital Management LLC, Renaissance Technologies LLC, Jennison Associates LLC, Champlain Investment Partners LLC, William Blair Investment Management LLC and American Century Companies Inc.. View Insider Buying and Selling for ABIOMED.

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABIOMED stock can currently be purchased for approximately $144.49.